DIAB s.r.o.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Chronic kidney disease2 trials
• Type 2 diabetes2 trials
• Coronary artery disease1 trial
• Stroke1 trial
• Type 1 diabetes1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Novo Nordisk A/S2 trials
• Amgen1 trial
• Bayer1 trial
• Boehringer Ingelheim1 trial

Running trials

• Active, not recruiting

  Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

  NCT07220759· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  NCT05869903· Phase 3· Eli Lilly and Company· Source

Closed trials

• Withdrawn

  A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

  NCT07357766· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source